EBMT: Some Key Facts:

• Established in 1974

• The EBMT is the leading, non-profit, scientific society

• The membership currently lists 3653 members from 527 centres across 57 countries

• 360,000 Haematopoietic Stem Cell Transplantations on 309,000 Patients are currently held in EBMT Registry

• 10 specialist Educational Courses organised annually across Europe

• 100 Retrospective Studies currently underway

• 8 ongoing Prospective Studies

• 89 Transplant Centres JACIE accredited
To foster **excellence in science** in order to further **improve the outcomes** of Stem Cell Transplantation and **inform** all concerned, including patients and their families about **developments** in the field.

This includes:

- Measuring trends in transplant activity
- Collecting and analysing patient transplant data in Europe
- Initiating pioneering prospective studies to improve clinical outcomes and advance patient care
- Networking and Educating Professionals
- Imposing strict quality standards
- Improving patient care
EBMT: In numbers

- 46 Publications in peer-review journals in 2009
- 150 Retrospective Analyses underway
- 8 Prospective Clinical Trials underway
- 350,888 Transplants in the EBMT Registry
- 30,293 HSCTs submitted to the Activity Survey in 2009
- 3612 EBMT Members across 57 Countries

The European Group for Blood and Marrow Transplantation
EBMT Executive Committee

President: Alejandro Madrigal (London, UK)
Secretary: Anna Sureda (Barcelona, Spain)
Treasurer: Jan Cornelissen (Rotterdam, NL)
EBMT Working Parties

- Acute Leukaemia: M Mohty (Nantes, France)
- Aplastic Anaemia: J Marsh (London, UK)
- Autoimmune Diseases: D Farge Bancel (Paris, France)
- Chronic Leukaemias: T de Witte (Nijmegan, NL)
- Immunobiology: A Velardi (Perugia, Italy)
- Inborn Errors: B Gaspar (London, UK)
- Infectious Diseases: S Cesaro (Verona, Italy)
- Late Effects: A Ticheli (Basel, Switzerland)
- Lymphoma: P Dreger (Heidelberg, Germany)
- Paediatric Diseases: C Peters (Vienna, Austria)
- Solid Tumours: M Bregni (Milan, Italy)

The European Group for Blood and Marrow Transplantation
EBMT Committees

Accreditation
Cord Blood
Developmental
Education
Nuclear Accident response
Outreach
Prospective Clinical Trials
Quality Assessment of autologous grafts
Statistical
The European Group for Blood and Marrow Transplantation
EBMT: Educating Professionals

• EBMT organises the only annual specialist educational course on Blood and Marrow Transplantation in association with the European School of Haematology (ESH).

• In addition, regular courses (all CME accredited) are organised on the application of HSCT in the treatment of specific diseases and conditions.

• Sharing the knowledge: All courses offer a number of outreach scholarships to facilitate the attendance of delegates from countries with lesser developed transplantation programmes.

• The ESH – EBMT Handbook on Haematopoietic Stem Cell Transplantation is the main reference guide for professionals working in the field. 50,000 copies are currently in circulation.

• EBMT has created a public online educational resource with the slides from EBMT-led educational programmes.
EBMT: Annual Congress - Networking & Education

- The EBMT organises an annual congress for scientific exchange between physicians, nurses, and data managers. The meeting takes place in a different European city at the end of March.

- The congress’ Scientific Programme is designed to inform physicians, nurses, data managers, quality managers of the cutting-edge advances in their field through a series of workshops, plenary sessions, controversy sessions, and educational sessions.

Number of participants 2000 - 2010

![Number of participants chart](chart.png)
EBMT: Supporting developing transplant programmes

A programme of activities has been developed by the EBMT, in collaboration with the European School of Haematology, aimed at supporting emerging BMT programmes and transplant centres in countries with limited resources and/or experience.

Key objectives of the Outreach programme include:

• Facilitating wider participation of members in EBMT activities

• Encouraging and promoting collaboration, through building long-lasting relationships between Blood and Marrow Transplantation developing projects to provide training and support for transplant programmes, with a view to harmonisation of BMT standards & practice across Europe and beyond

• Identifying resources and funding to support Outreach initiatives
The European Group for Blood and Marrow Transplantation

EBMT: Patients, Families, Donors and Carers

EBMT organises an annual Patient & Family Day. The key objectives are as follows:

• to encourage communication between patients, scientists and clinicians working on curing their illnesses

• to bring together patient associations to foster long-lasting collaborations

• to promote a sense of solidarity between patients suffering from the same disease
The European Group for Blood and Marrow Transplantation
**EBMT: JACIE** (Joint Accreditation Committee-ISCT & EBMT)

• The Joint Accreditation Committee-ISCT & EBMT is a non-profit body established in 1998 for the purposes of **assessment and accreditation** in the field of haematopoietic stem cell (HSC) transplantation.

• The funding to establish JACIE under the EBMT was achieved through a successful EU grant application.

• JACIE’s primary aim is to **promote high quality patient care** and laboratory performance in haematopoietic stem cell collection, processing and transplantation centres through an internationally recognised system of accreditation.

• 200 transplant centres have already applied for JACIE worldwide and JACIE accreditation is fast becoming a **necessary standard** for transplant centres to achieve.
2. JACIE Accreditation

Cumulative initial applications & all inspections

- Initial applications
- Inspections

The European Group for Blood and Marrow Transplantation
% distribution of initial applications by country

- Czech Republic: 1,5%
- Austria: 1,0%
- Saudi Arabia: 0,5%
- Poland: 0,5%
- Turkey: 0,5%
- Israel: 0,5%
- United Kingdom: 21,4%
- Germany: 16,0%
- France: 14,1%
- Italy: 13,1%
- Netherlands: 10,2%
- Spain: 7,8%
- Belgium: 4,9%
- Switzerland: 5,3%
- Sweden: 1,5%
JACIE registrations as % of EBMT members by country

The European Group for Blood and Marrow Transplantation
EBMT Registry

The European Group for Blood and Marrow Transplantation
The EBMT Registry uses a central data management system to collect data on patients treated with a haematopoietic stem cell transplant (HSCT) according to indication (type of disease), donor type (allogeneic/autologous) and stem cell source (bone marrow/peripheral blood/cord blood).

- The Registry stores data from over 360,000 transplants with over 26,000 new transplants reported each year, and is accessible to EBMT members, representing the largest transplant database available to them today.

- From this database, studies investigating predictive factors for transplantation, outcomes of diseases, frequencies of stem cell transplantation and the outcomes of different transplantation techniques can be analysed.

- The information available can be used to simulate a stem cell transplant based on the experience gained over the past 30 years. The database also enables progress in stem cell transplantation over the past three decades to be tracked and is used for quality control purposes.
A number of collaborative registry studies have been published with the CIBMTR (Center for International Blood and Marrow Transplant Research) in the USA.

Data Sharing agreements with donor registries and other databases of other groups are currently in progress with the objective of facilitating data reporting to centres, providing a service to donor registries for their regulatory requirements, enlarging the scope, and maximizing data quality in the Registry.

The data held in the EBMT Registry is becoming increasingly interesting for the official agencies responsible for national health programmes.
<table>
<thead>
<tr>
<th>Condition</th>
<th>Count 2014</th>
<th>Count 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute leukaemias: AML</td>
<td>43.779</td>
<td>47.995</td>
</tr>
<tr>
<td>Acute leukaemias: ALL</td>
<td>27.342</td>
<td>29.447</td>
</tr>
<tr>
<td>Acute leukaemias: other/unknown</td>
<td>1.513</td>
<td>1.686</td>
</tr>
<tr>
<td>Chronic leukaemias: CML</td>
<td>19.389</td>
<td>20.879</td>
</tr>
<tr>
<td>Chronic leukaemias: CLL</td>
<td>4.221</td>
<td>4.676</td>
</tr>
<tr>
<td>Chronic leukaemias: other/unknown</td>
<td>435</td>
<td>477</td>
</tr>
<tr>
<td>Lymphomas: NHL</td>
<td>61.618</td>
<td>68.194</td>
</tr>
<tr>
<td>Lymphomas: Hodgkins</td>
<td>21.084</td>
<td>23.789</td>
</tr>
<tr>
<td>Lymphomas: other/unknown</td>
<td>1.483</td>
<td>1.611</td>
</tr>
<tr>
<td>Multiple myeloma/Plasma cell disorders</td>
<td>58.731</td>
<td>79.960</td>
</tr>
<tr>
<td>Solid tumours</td>
<td>32.426</td>
<td>42.896</td>
</tr>
<tr>
<td>Myelodysplastic/myeloproliferative</td>
<td>15.564</td>
<td>17.577</td>
</tr>
<tr>
<td>Aplastic anaemias</td>
<td>7.248</td>
<td>8.015</td>
</tr>
<tr>
<td>Primary immune deficiency</td>
<td>2.402</td>
<td>2.745</td>
</tr>
<tr>
<td>Inborn errors: other / unspecified</td>
<td>1.534</td>
<td>1.735</td>
</tr>
<tr>
<td>Histiocytic</td>
<td>633</td>
<td>695</td>
</tr>
<tr>
<td>Autoimmune diseases</td>
<td>1.158</td>
<td>1.190</td>
</tr>
<tr>
<td>Haemoglobinopathies</td>
<td>3.546</td>
<td>3.746</td>
</tr>
<tr>
<td>Other/unknown</td>
<td>582</td>
<td>692</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>304.688</strong></td>
<td><strong>358.005</strong></td>
</tr>
</tbody>
</table>
The EBMT Membership

EBMT members are mainly centres active in the transplantation of haematopoietic stem cells. Membership is also open to individuals, companies and other organisations actively involved in the care of donors and recipients of haematopoietic stem cells.

The membership lists **3612** members from **536** centres in **57** countries

Central Registry and **13** affiliated registries (11 national, 2 others)

The EBMT is sponsored by **17** Corporate Patrons
Clinical Trials

The European Group for Blood and Marrow Transplantation
The European Group for Blood and Marrow Transplantation

EBMT: Initiating pioneering prospective studies to improve clinical outcomes and advance patient care

• Academic prospective clinical trials form a key part of patient-oriented clinical research, and create the basis for continuously improving patient care.

• As treatment outcomes for many hematological diseases have progressively improved, it has become necessary to conduct larger and larger trials to demonstrate meaningful improvements in the standard of care.

• With this background, the EBMT established several years ago the PCTC and the Clinical Trials Office (CTO), with the aim to allow for a pan EBMT commitment to opening and running large prospective clinical trials.
EBMT: Plans for the future

- Improve Med B submission
- Include more patients in clinical studies
- Change in clinical study philosophy
- Non-interventional studies
- Define optimal treatment from diagnosis
- Interaction members and the board
- Interaction with disease related scientific groups